Prognose

Vi har ingen analytikerdata for denne virksomhed.

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • Demant rises sharply after double upgrade by BofA

    The Demant share climbed about 3.5% today after BofA Securities raised its rating from "Underperform" to "Buy" and increased the price target from DKK 170 to DKK 280. BofA justified the upgrade with stronger market growth in the first quarter, improved demand for the Oticon Zeal product, raised EPS forecasts for 2026 and 2027, and lower capital costs. The revaluation pushed the stock toward the new price target and supports a recovery thesis for Demant. » Mere på de.investing.com


  • Demant exceeds Q1 revenue forecast thanks to Oticon Zeal and acquisitions

    Demant reports Q1 2026 revenue of USD 6.25 billion, 2.46% above the USD 6.1 billion forecast. Total growth was 16%, driven by 6% organic growth and 10% acquisition-driven growth (mainly from the acquisition of KIND); EPS met expectations. Strong sales in North America and Europe and the launch of Oticon Zeal lifted the gross margin, and the stock rose 0.97% after hours to USD 209.2. Management confirms the 2026 outlook and remains confident about further product launches in the second half of the year. » Mere på de.investing.com


  • Demant beats Q1 revenue forecast thanks to hearing-aid growth, stock jumps sharply

    Demant reported Q1 2026 revenue of USD 6.25 billion, exceeding the USD 6.1 billion forecast. Drivers were 6% organic growth and roughly 10% acquisition-driven growth following the integration of KIND, as well as the product launch of Oticon Seal, which led to an expansion of gross margin. The stock rose 10.9% to USD 232 after the announcement. Management confirmed the full-year guidance for organic growth of 3–6% and an EBIT range of DKK 4.1–4.5 billion, but cited currency risks and potential market saturation as challenges. » Mere på de.investing.com


  • William Demant falls 13% after quarterly results

    William Demant reported acquisition-driven revenue growth in Q4 2025, while EBIT before special items fell 10% and free cash flow declined 11%. The takeover of the KIND group increased net debt and pushed the leverage ratio to 3.4, prompting management to suspend share buybacks and prioritize debt reduction. Newly introduced premium hearing aid Oticon Seal is expected to drive growth but failed to reassure investors. For 2026 the company expects organic growth of 3–6% and an EBIT of DKK 4.1–4.5 billion; a return to the leverage target is planned within 18–24 months. » Mere på de.investing.com


  • Demant acquires Kind and becomes Germany's largest hearing-aid chain

    The Federal Cartel Office has approved the takeover of around 600 Kind branches by the Danish group Demant. Demant is also buying Audifon, the manufacturer owned by Kind, combining about 350 of its own branches in Germany with the acquired locations. The authority considers there to be sufficient competition from other chains, opticians and regional providers despite the merger. The Kind brand name is to be retained, and the previous owning family will withdraw after the transaction is completed. » Mere på spiegel.de

I 2000 har Demant allerede udloddet 0,0802 € i udbytte. Den seneste udlodning fandt sted i maj 2000.

Virksomhedstal

I det seneste kvartal havde Demant en omsætning på 1,73 mia. € og et nettoresultat på 158,11 mio. €

(EUR) juni 2026
YoY
Omsætning 1,73 mia. -
Bruttofortjeneste 1,34 mia. -
Nettoresultat 158,11 mio. -
EBITDA 413,66 mio. -

Fundamentale data

Nøgletal Værdi
Markedsværdi
10,25 mia. €
Antal aktier
210,9 mio.
Højeste/laveste i 52 uger
49,02 € - 25,57 €
Udbytte Nej
Beta
0,76
P/E (PE Ratio)
44,72
PEG (PEG Ratio)
-1,54
K/I (PB Ratio)
6,41
P/S (PS Ratio)
2,93

Virksomhedsprofil

Demant A/S, et selskab inden for høreapparater og lydteknologi, udvikler, fremstiller og sælger produkter og udstyr til at forbedre folks hørelse i Europa, Nordamerika, Stillehavsregionen, Asien og internationalt. Selskabet opererer i to segmenter, Hearing Healthcare og Communications. Segmentet Hearing Healthcare tilbyder høreimplantater og høreapparater, hørepleje og diagnostiske produkter. Segmentet Communications leverer headsets til samarbejdsorienterede arbejdsmarkeder og gamingmarkedet under varemærket EPOS. Selskabet var tidligere kendt som William Demant Holding A/S og skiftede navn til Demant A/S i marts 2019. Demant A/S blev grundlagt i 1904 og har hovedkontor i Smørum, Danmark.

Navn
Demant
CEO
Søren Nielsen
Hjemsted Smørum, ze
Danmark
Websted
Sektor
Sundhed
Branche
Sundhedsudstyr og -produkter
Børsnotering
08.05.2000
Medarbejdere 26.704

Tickersymboler

Børs Symbol
Pnk
WILLF
Nasdaq Copenhagen
DEMANT.CO
Copenhagen
DEMANT.CO
Frankfurt
WDH1.F
Düsseldorf
WDH1.DU
London
0RGT.L
SIX
WDH.SW
München
WDH1.MU
Wien
DEMA.VI
🍪

Parqet  bruger cookies. Læs mere